TLGT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Šios dienos apimtis	72.25M
Vidutinė apimtis	7.97M
Rinkos kapitalizacija	0.00
EPS	$-0.140 ( 2021-08-16 )
Last Dividend	$47.50 ( 1995-12-13 )
Next Dividend	$0 ( N/A )
P/E	-0.0403
ATR14	$0.0270 (15.56%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-21	Ben-maimon Carole	Buy	150 000	Restricted Stock Units
2021-07-21	Celentano John E	Buy	150 000	Restricted Stock Units
2021-07-21	Marth William S	Buy	150 000	Restricted Stock Units
2021-07-21	Pate R Carter	Buy	150 000	Restricted Stock Units
2021-07-16	Yachmetz Philip K	Buy	7 835	Restricted Stock Units

INSIDER POWER
0.00
Last 94 transactions
Buy: 6 929 847 \| Sell: 975 703

Tūris Koreliacija

Ilgas: -0.41 (neutral)

Trumpas: -0.94 (very strong negative)

Signal:(21.732) Possible Trading Opportunity Present (swing)

Teligent Inc (NEW JERSEY) Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.953
PAIC	0.934
RMRM	0.914
GOODM	0.907
MTSL	0.856
SPRT	0.848
FEYE	0.842

10 Labiausiai neigiamai susiję koreliacijos
NETE	-0.948
AMRB	-0.934
MMAC	-0.907
LWAC	-0.883
RAVN	-0.872
SRAC	-0.862
BOCH	-0.804

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Teligent Inc (NEW JERSEY) Koreliacija - Valiuta/Žaliavos

0.20
( neutral )

-0.65
( moderate negative )

0.00
( neutral )

-0.09
( neutral )

0.51
( weak )

-0.27
( neutral )

Teligent Inc (NEW JERSEY) Finansinės ataskaitos

Annual	2020
Pajamos:	$45.31M
Bruto pelnas:	$45.31M (100.00 %)
EPS:	$0

FY	2020
Pajamos:	$45.31M
Bruto pelnas:	$45.31M (100.00 %)
EPS:	$0

FY	2019
Pajamos:	$65.90M
Bruto pelnas:	$23.52M (35.70 %)
EPS:	$-4.70

FY	2017
Pajamos:	$67.25M
Bruto pelnas:	$27.37M (40.70 %)
EPS:	$-2.80

Financial Reports:

No articles found.

Teligent Inc (NEW JERSEY) Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teligent Inc (NEW JERSEY) Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$47.50	1995-12-13
Last Dividend	$47.50	1995-12-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$47.50	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
1995	$0	0.00%
1996	$0	0.00%
1997	$0	0.00%
1998	$0	0.00%
1999	$0	0.00%
2000	$0	0.00%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0	1.500	-1.111	-1.667	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.916	0.800	5.42	4.34	[1 - 3]
quickRatioTTM	0.744	0.800	-0.329	-0.263	[0.8 - 2.5]
cashRatioTTM	0.257	1.500	9.68	10.00	[0.2 - 2]
debtRatioTTM	1.636	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.217	2.00	-0.0725	-0.145	[0 - 30]
freeCashFlowPerShareTTM	-0.270	2.00	-0.135	-0.270	[0 - 20]
debtEquityRatioTTM	-1.246	-1.500	-4.98	7.47	[0 - 2.5]
grossProfitMarginTTM	1.000	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.988	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.122	1.000	-1.790	-1.790	[0.2 - 2]
assetTurnoverTTM	0.540	0.800	9.73	7.79	[0.5 - 2]
Total Score				3.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0	1.000	-0.101	0	[1 - 100]
returnOnEquityTTM	0	2.50	-0.714	-1.667	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.270	2.00	-0.0899	-0.270	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.217	2.00	-0.0725	-0.145	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.370	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.721

Teligent Inc (NEW JERSEY)

Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.